J.Jpn. Surg. Soc.. 92(9): 1330-1333, 1991

---

Report on the annual meeting

ADOPTED IMMUNOCHEMOTHERAPY USING IL-2 AND SPLEEN LAK CELL
―RANDOMIZED STUDY―

Thirty patients with hepatoceullar carcinoma who underwent hepatic resection during the recent 2 years in our department were randomized. We derived LAK cells from the autologous spleen removed during operation. The cultivation of LAK cells were done with IL-2. Adriamycin 20mg/body was injected into hepatic artery via subcutaneous implanted reservoir on the 8th postoperative day. In group A, 1.0～7.6×10⁹ LAK cells were injected i. a on day, 10, 14, and 21 after operation. IL-2 of 5×10⁵ JU were also injected i.a. during 3 weeks. Group B patients were treated only by adriamycin. High fever was seen in all patients belonged to group A. Twelve patients in each group were evaluable. Recurrence rate 8.3% in group A was significantly lower than 50% in group B. In experimental study, accumulation of ¹¹¹In-oxine labelled LAK cells in mouse 3LL lung cancer was augumented in splenectomized ones. Adopted immunotherapy by spleen LAK-cells may be effective and safe treatment to preventing recurrence of hepatocellular carcinoma after hepatectomy.

---

---

To read the PDF file you will need Adobe Reader installed on your computer.